News
-
-
PRESS RELEASE
Medacta Group SA: Medacta Group SA reports an excellent performance in 2024 with an adjusted EBITDA margin1 in constant currency of 28.0%
Medacta Group SA reports excellent 2024 performance with 28.0% adjusted EBITDA margin. Revenue up 16.2% in constant currency. Board proposes CHF 0.69 per share distribution. Outlook targets 13-15% revenue growth & 27% EBITDA margin for 2025 -
-
-
-
PRESS RELEASE
Medacta Group SA reports significant above-market revenue growth of 16.2% in constant currency in 2024
Medacta Group SA reports 16.2% revenue growth in constant currency in 2024, driven by all geographic markets and business lines. CEO Francesco Siccardi expresses pride in team's achievements -
-
PRESS RELEASE
Medacta unveils the extended enhancements to its Hip Revision Platform
Medacta announces extended enhancements to its Hip Revision Platform in the European market to provide innovative solutions for complex procedures, including femoral and acetabular solutions with advanced features and medical education support -
-
PRESS RELEASE
Medacta Hosts Inaugural Capital Markets Day, Showcasing Responsible Innovation and Effective Growth Strategy
Medacta Group SA hosts its first Capital Markets Day, presenting responsible innovation and effective growth strategy to investors. Key areas include patient-focused commitment, product development, and global market expansion